Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 326 articles:
HTML format



Single Articles


    July 2025
  1. HU A, Wen X, Tian J, Wang Z, et al
    RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.
    Oral Oncol. 2025;167:107464.
    PubMed     Abstract available


  2. RIJKEN JA, de Ridder M, Devriese LA, Breimer GE, et al
    Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report.
    Oral Oncol. 2025;166:107392.
    PubMed     Abstract available


  3. RONDI P, Mattavelli D, Rampinelli V, Schreiber A, et al
    The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2.
    Oral Oncol. 2025;166:107388.
    PubMed     Abstract available


  4. SOMAY E, Bascil S, Topkan E, Selek U, et al
    Re: "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors" by Kamel et al.
    Oral Oncol. 2025;167:107457.
    PubMed    


    June 2025
  5. MALGAVE DS, Hartman CM, Kramer JR, Richardson PA, et al
    Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.
    Oral Oncol. 2025;167:107446.
    PubMed     Abstract available


  6. RAJATHIRAJAN SD
    Commentary on, "Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging".
    Oral Oncol. 2025;167:107453.
    PubMed    


  7. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact: Running title: Massive nasal bleeding in NPC.
    Oral Oncol. 2025;167:107456.
    PubMed     Abstract available


  8. DAUNGSUPAWONG H, Wiwanitkit V
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: Comment.
    Oral Oncol. 2025;167:107454.
    PubMed    


  9. SAMUEL CHAN SW, Amer Al Maqrashi ZA, Kim DH, Choi D, et al
    Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.
    Oral Oncol. 2025;167:107439.
    PubMed    


  10. NGO DQ, Truong DS, Le DT, Hoang TM, et al
    Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: surgical and oncological outcomes.
    Oral Oncol. 2025;167:107406.
    PubMed     Abstract available


  11. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    PubMed     Abstract available


  12. KAMEL S, Humbert-Vidan L, Kaffey Z, Mirbahaeddin S, et al
    Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors.
    Oral Oncol. 2025;167:107337.
    PubMed     Abstract available


  13. MAK CH, Cao LM, Luo HY, Zhou K, et al
    Postoperative complications of neck dissection for head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107430.
    PubMed     Abstract available


  14. YANG X, Li R
    Reconsidering the prognostic value of HRQOL in head and neck cancer.
    Oral Oncol. 2025;167:107421.
    PubMed    


  15. YAN Y, Wang Z, Sun Y
    Comment on: Margins do not impact recurrence and survival in advanced laryngeal cancer-A retrospective cohort analysis.
    Oral Oncol. 2025;167:107427.
    PubMed    


  16. LIANG YJ, Luo MJ, Wen DX, Wang P, et al
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.
    Oral Oncol. 2025;167:107404.
    PubMed     Abstract available


  17. KIM MJ, Koo BS, Cho KJ, Lee SH, et al
    Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments.
    Oral Oncol. 2025;165:107342.
    PubMed     Abstract available


  18. GARSET-ZAMANI M, Makouei F, Agander TK, Lelkaitis G, et al
    Feasibility of 3D ultrasound for intraoperative tumor margin assessment in transoral robotic surgery for oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;165:107330.
    PubMed     Abstract available


  19. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    PubMed     Abstract available


  20. JANG HB, Lee DH, Lim SC
    Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience.
    Oral Oncol. 2025;165:107317.
    PubMed     Abstract available


  21. CHELVARAJAH RC, Liu Y, Su J, Abdalaty AH, et al
    Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma.
    Oral Oncol. 2025;165:107310.
    PubMed     Abstract available


    May 2025
  22. HINTZE JM, Cleere E, Soo A, Timon C, et al
    Margins do not impact recurrence and survival in advanced laryngeal cancer - A retrospective cohort analysis.
    Oral Oncol. 2025;167:107402.
    PubMed     Abstract available


  23. BAIJU DC, Ravi J, Sarma M, Sureshan M, et al
    Detection of hotspot mutations in oral cancer through Ion AmpliSeq cancer hotspot panel v.2.0: A circulating DNA fragmentomics approach in the Northeast Indian population.
    Oral Oncol. 2025;166:107387.
    PubMed     Abstract available


  24. JEYARAJ G
    Commentary on, "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;166:107401.
    PubMed    


  25. LIU X, Xue S
    Comment on: Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2025;166:107368.
    PubMed    


  26. VERDONCK-DE LEEUW IM, Lissenberg-Witte BI, de Bree R, Buffart LM, et al
    The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study.
    Oral Oncol. 2025;166:107367.
    PubMed     Abstract available


  27. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    PubMed     Abstract available


  28. TONSBEEK AM, van der Lely JN, Bulstra L, Venema J, et al
    Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction.
    Oral Oncol. 2025;166:107363.
    PubMed     Abstract available


  29. MALI SB
    Corrigendum to "Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer" [Oral Oncol. 51 (2015) 565-569].
    Oral Oncol. 2025 May 10:107357. doi: 10.1016/j.oraloncology.2025.107357.
    PubMed    


  30. MALI SB
    Corrigendum to "RNA interference in oral cancer" [Oral Oncol. 51 (2015) e2-e3].
    Oral Oncol. 2025 May 9:107358. doi: 10.1016/j.oraloncology.2025.107358.
    PubMed    


  31. SHAIKH N, Pandey M, Manna S, Gawde J, et al
    Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy.
    Oral Oncol. 2025;165:107346.
    PubMed     Abstract available


  32. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    PubMed     Abstract available


  33. ONAGA R, Enokida T, Kuno H, Hiyama T, et al
    Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.
    Oral Oncol. 2025;165:107351.
    PubMed     Abstract available


  34. ZHU X, Xu H, Zhao Y, Diao W, et al
    Single-cell transcriptomics reveal the effects of chemoimmunotherapy on hypopharyngeal cancer and its tumor microenvironment.
    Oral Oncol. 2025;165:107347.
    PubMed     Abstract available


  35. PEI Y, Yang Z, Mao Y, Chen X, et al
    Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions.
    Oral Oncol. 2025;165:107333.
    PubMed     Abstract available


  36. XIAO X, Liu T, Lu M, Song Z, et al
    Comment on the role of lymph node level ratio in predicting prognosis of pN1 head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107344.
    PubMed    


  37. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    PubMed     Abstract available


  38. MARCHI F, Del Bon F, Chu F, Sampieri C, et al
    Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery.
    Oral Oncol. 2025;164:107264.
    PubMed     Abstract available


  39. CANALI L, Russo E, Pangallo S, Bussu F, et al
    Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2025;164:107270.
    PubMed     Abstract available


  40. MOTTA G, Magno C, Castagna L, De Berardinis T, et al
    Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx.
    Oral Oncol. 2025;164:107260.
    PubMed     Abstract available


  41. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    PubMed     Abstract available


    April 2025
  42. MALI SB
    Corrigendum to "Proteomics for oral cancer" [Oral Oncol. 50(11) (2014) e67].
    Oral Oncol. 2025 Apr 30:107338. doi: 10.1016/j.oraloncology.2025.107338.
    PubMed    


  43. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    PubMed     Abstract available


  44. SILVA CUNHA JL
    Comment on "Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;165:107336.
    PubMed    


  45. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    PubMed     Abstract available


  46. ARDILA CM
    Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy.
    Oral Oncol. 2025;165:107303.
    PubMed    


  47. JEYARAJ G
    Commentary on, "Molecular features of T and N stage progression in laryngeal cancer.".
    Oral Oncol. 2025;165:107331.
    PubMed    


  48. BARCELONA MVN, Waldron J, Sullivan BO, Su J, et al
    Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.
    Oral Oncol. 2025;165:107299.
    PubMed     Abstract available


  49. YAO CMKL, Hueniken K, Huang SH, Liu G, et al
    Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer.
    Oral Oncol. 2025;165:107304.
    PubMed     Abstract available


  50. JEYARA G
    Commentary on, "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.".
    Oral Oncol. 2025;165:107320.
    PubMed    


  51. ZHOU P, Zhu Y, Xu B, Jiang X, et al
    Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
    Oral Oncol. 2025;165:107316.
    PubMed     Abstract available


  52. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    PubMed     Abstract available


  53. KOSKENNIEMI AR, Huusko T, Routila J, Jalkanen S, et al
    Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107287.
    PubMed     Abstract available


  54. JEYARAJ G
    Commentary on, "Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial".
    Oral Oncol. 2025;165:107302.
    PubMed    


  55. LI N, Zeng PYF, Kim HAJ, Karimi A, et al
    Molecular features of T and N stage progression in laryngeal cancer.
    Oral Oncol. 2025;165:107283.
    PubMed     Abstract available


  56. BURGER AVM, Koot MA, van Balen DEM, Schaeffers AWMA, et al
    Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.
    Oral Oncol. 2025;164:107246.
    PubMed     Abstract available


  57. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
    Oral Oncol. 2025 Apr 11:107292. doi: 10.1016/j.oraloncology.2025.107292.
    PubMed    


  58. MA J, Brooks C, Tasoulas J, Wind LS, et al
    Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;164:107293.
    PubMed    


  59. SLATER NN, Herberger L, Farsi S, Rogers AL, et al
    Assessing barriers to adjuvant therapy among patients with head and neck cancer in Arkansas.
    Oral Oncol. 2025;164:107290.
    PubMed     Abstract available


  60. XIAO J, You M, Song Y, Gao R, et al
    Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.
    Oral Oncol. 2025;164:107288.
    PubMed     Abstract available


  61. VIANNA CAMOLESI GC, Prado-Pena IB, Gomez-Caamano A, Victoria-Fernandez C, et al
    Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial.
    Oral Oncol. 2025;164:107266.
    PubMed     Abstract available


  62. JEYARAJ G
    Commentary on, "Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort".
    Oral Oncol. 2025;164:107285.
    PubMed    


  63. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    PubMed     Abstract available


    March 2025
  64. LIN N, Zhou X, Wang Y, Zhou J, et al
    Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
    Oral Oncol. 2025;164:107269.
    PubMed     Abstract available


  65. JEYARAJ G
    Commentary on, "Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study".
    Oral Oncol. 2025;163:107256.
    PubMed    


  66. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    PubMed    


  67. MATHEW JM, Busca I, Baskurt Z, Giuliani M, et al
    Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.
    Oral Oncol. 2025;163:107250.
    PubMed     Abstract available


  68. DONG Z, Wang GY, Qin GJ, Dai DY, et al
    Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
    Oral Oncol. 2025;163:107223.
    PubMed     Abstract available


  69. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    PubMed     Abstract available


  70. PETRELLI F, Lorini L, Paderno A, Carioli D, et al
    Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;163:107248.
    PubMed     Abstract available


  71. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    PubMed     Abstract available


  72. GAZZINI L, Festa BM, Calabrese L
    Elective neck dissection: Are we bound to outdated concepts?
    Oral Oncol. 2025;163:107245.
    PubMed    


  73. WU WJ, An PG, Liu Q, Zhang ZQ, et al
    Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis.
    Oral Oncol. 2025;162:107218.
    PubMed     Abstract available


  74. YANG F, Peng W, Wei H, Li X, et al
    Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.
    Oral Oncol. 2025;162:107187.
    PubMed     Abstract available


  75. YE Z, Li X, Xie F, Sun J, et al
    A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma.
    Oral Oncol. 2025;162:107185.
    PubMed     Abstract available


  76. CHARLTON A, Mughal Z, Sharin F, Sahota RB, et al
    Prevalence of synchronous bilateral/contralateral tonsil carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2025;162:107180.
    PubMed     Abstract available


  77. DE VETTE SPM, van Rijn-Dekker MI, Van den Bosch L, Keijzer K, et al
    Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.
    Oral Oncol. 2025;163:107224.
    PubMed     Abstract available


  78. MIYAGUCHI J, Shiga K, Katagiri K, Saito D, et al
    Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer.
    Oral Oncol. 2025;163:107228.
    PubMed     Abstract available


    February 2025
  79. WICZUK-WICZEWSKA M, Bernaciak J, Nogal P, Bugaj A, et al
    Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report.
    Oral Oncol. 2025;163:107227.
    PubMed     Abstract available


  80. JEYARAJ G
    Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.".
    Oral Oncol. 2025;163:107231.
    PubMed    


  81. TINO RB, Roach MA, Fuentes GD, Agrawal A, et al
    Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy".
    Oral Oncol. 2025;162:107220.
    PubMed    


  82. MEEKER BS MO, Katragadda A, Alsavaf MB, Birkenbeuel J, et al
    Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry.
    Oral Oncol. 2025;162:107219.
    PubMed     Abstract available


  83. YANG H, Sun P, Wang Y, Wang X, et al
    Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
    Oral Oncol. 2025;162:107211.
    PubMed     Abstract available


  84. IQBAL MS, West N, Kovarik J, Jackson M, et al
    Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
    Oral Oncol. 2025;162:107214.
    PubMed    


  85. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    PubMed     Abstract available


  86. MO Y, Wei Y, Liang L, Wu T, et al
    Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
    Oral Oncol. 2025;161:107160.
    PubMed     Abstract available


  87. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
    Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
    Oral Oncol. 2025;161:107178.
    PubMed     Abstract available


  88. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
    Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
    Oral Oncol. 2025;161:107139.
    PubMed     Abstract available


  89. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
    Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
    Oral Oncol. 2025;161:107170.
    PubMed     Abstract available


  90. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
    High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;161:107171.
    PubMed     Abstract available


  91. KWON JJ, Milner TD, Kurten C, Pang EH, et al
    Towards transcervical ultrasound-guided transoral robotic surgery.
    Oral Oncol. 2025;161:107167.
    PubMed     Abstract available


  92. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    PubMed     Abstract available


    January 2025
  93. WENGER TA, Gao J, Nurimba M, Phung PG, et al
    Palliative care utilization among head and neck cancer patients: A population-based analysis.
    Oral Oncol. 2025;162:107205.
    PubMed     Abstract available


  94. CHEN L, Fang R, Cai Z, Huang B, et al
    CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;162:107181.
    PubMed     Abstract available


  95. YIN Z, Zhao H, Zhu C, Fang J, et al
    Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2025;161:107195.
    PubMed    


  96. JIANG H, Zhou L, Zhao T, Zou G, et al
    Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
    Oral Oncol. 2025;161:107192.
    PubMed    


  97. JIANG H, Zhou L, Zou G, Zhang H, et al
    Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
    Oral Oncol. 2025;161:107191.
    PubMed    


  98. LI MH, Hu YJ, Shan HM, Gao XL, et al
    The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
    Oral Oncol. 2025;161:107193.
    PubMed     Abstract available


  99. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    PubMed     Abstract available


  100. TOPKAN E, Somay E, Selek U
    Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
    Oral Oncol. 2025;161:107175.
    PubMed    


  101. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
    Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2025;161:107177.
    PubMed    


  102. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    PubMed     Abstract available


  103. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
    Oral Oncol. 2025;161:107146.
    PubMed     Abstract available


  104. XU S, He J, Liu Z, Pei Y, et al
    Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;161:107161.
    PubMed     Abstract available


    December 2024
  105. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    PubMed     Abstract available


  106. LIU Y, Fu N, Liu H, Su S, et al
    Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
    Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
    PubMed    


  107. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    PubMed     Abstract available


  108. FANG Q, Yuan J, Zhang X, Dai L, et al
    Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
    Oral Oncol. 2024;161:107149.
    PubMed     Abstract available


  109. PRICE JM, Garcez K, Hughes C, Lee LW, et al
    The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2024;161:107138.
    PubMed     Abstract available


  110. STRUCKMEIER AK, Gosau M, Smeets R
    Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
    Oral Oncol. 2024;161:107145.
    PubMed     Abstract available


  111. MEGWALU UC, Ma Y, Divi V
    Association of race and ethnicity with quality of care among head and neck cancer patients in California.
    Oral Oncol. 2024;161:107144.
    PubMed     Abstract available


  112. PACE GM, Costantino A, De Virgilio A
    Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
    Oral Oncol. 2024;161:107142.
    PubMed    


  113. YU ST, Huang D, Xiong C, Xie R, et al
    Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
    Oral Oncol. 2024;161:107140.
    PubMed     Abstract available


  114. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
    Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
    Oral Oncol. 2024;160:107136.
    PubMed     Abstract available


  115. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
    Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
    Oral Oncol. 2024;160:107134.
    PubMed    


  116. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
    Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;160:107126.
    PubMed     Abstract available


  117. LI H, Lou L, Du J, Li M, et al
    Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;160:107129.
    PubMed     Abstract available


  118. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
    Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2024;159:107091.
    PubMed     Abstract available


  119. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
    Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
    Oral Oncol. 2024;159:107068.
    PubMed     Abstract available


  120. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
    Surgical and functional outcomes after salvage oropharyngectomy.
    Oral Oncol. 2024;159:107050.
    PubMed     Abstract available


  121. KORIC A, Chang CP, Hu S, Snyder J, et al
    Oral health-related quality of life among oropharyngeal cancer survivors.
    Oral Oncol. 2024;159:107062.
    PubMed     Abstract available


  122. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
    Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
    Oral Oncol. 2024;159:107048.
    PubMed     Abstract available


  123. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
    Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107031.
    PubMed     Abstract available


  124. GREEN L, McDowell L, Ip F, Tapia M, et al
    Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107032.
    PubMed     Abstract available


  125. LU YT, Lin CW, Su SC, Ho YT, et al
    L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
    Oral Oncol. 2024;159:107038.
    PubMed     Abstract available


  126. STAIBANO P, Au M, Xie M, Gupta MK, et al
    Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
    Oral Oncol. 2024;159:107033.
    PubMed     Abstract available


  127. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
    Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
    Oral Oncol. 2024;160:107130.
    PubMed     Abstract available


    November 2024
  128. MARRET G, Lamy C, Vacher S, Cabel L, et al
    Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
    Oral Oncol. 2024;160:107111.
    PubMed     Abstract available


  129. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    PubMed    


  130. LIU Y, Fu N, Liu H, Su S, et al
    Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2024;160:107120.
    PubMed     Abstract available


  131. YAN C, Wang R, Zhang C, Lin G, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
    Oral Oncol. 2024;160:107119.
    PubMed     Abstract available


  132. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    PubMed     Abstract available


  133. LI S, Zhao T, Liu N, Li Y, et al
    Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
    Oral Oncol. 2024;159:107094.
    PubMed     Abstract available


  134. YANG B, Dai X, Li Z, Wu Z, et al
    Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107105.
    PubMed     Abstract available


  135. RENGASAMY G, Priya Veeraraghavan V
    Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107086.
    PubMed    


  136. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
    Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107101.
    PubMed     Abstract available


  137. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    PubMed     Abstract available


  138. LENNON SILVA CUNHA J
    In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
    Oral Oncol. 2024;159:107096.
    PubMed    


  139. TOPKAN E, Somay E, Ozturk D, Selek U, et al
    Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
    Oral Oncol. 2024;159:107099.
    PubMed    


  140. SHANG K, Li T, Chen Y, Luo X, et al
    Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
    Oral Oncol. 2024;159:107087.
    PubMed     Abstract available


  141. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
    Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
    Oral Oncol. 2024;158:106996.
    PubMed    


  142. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
    Results of CO2 laser surgery in laryngeal papillomatosis.
    Oral Oncol. 2024;158:107004.
    PubMed     Abstract available


  143. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
    The role of microbiota in nasopharyngeal cancer: Where do we stand?
    Oral Oncol. 2024;158:106982.
    PubMed     Abstract available


  144. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
    Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107097.
    PubMed    


  145. HIMANI
    Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107093.
    PubMed    


    October 2024
  146. MUTHAMIZH S, Balachandran S, Dilipan E
    Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107095.
    PubMed    


  147. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
    Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2024;159:107085.
    PubMed     Abstract available


  148. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    PubMed     Abstract available


  149. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
    Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
    Oral Oncol. 2024;159:107081.
    PubMed    


  150. LI D, Lopez A, Shrivastava N, Chan W, et al
    Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
    Oral Oncol. 2024;159:107069.
    PubMed     Abstract available


  151. WU WB, Xia L, Feng ZK, Liang JL, et al
    Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107071.
    PubMed     Abstract available


  152. ZANG Y, Lu Y, Yu J, Dong Q, et al
    FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107066.
    PubMed     Abstract available


  153. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    PubMed     Abstract available


  154. LIU C, Zhao H, Lu Y, Xia Y, et al
    Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
    Oral Oncol. 2024;159:107051.
    PubMed     Abstract available


  155. SONG Y, Zhang Y, Bai Y, Wang T, et al
    Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
    Oral Oncol. 2024;159:107067.
    PubMed     Abstract available


  156. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
    Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
    Oral Oncol. 2024;159:107070.
    PubMed     Abstract available


  157. HE SQ, Liu GY, Yu YH, Wang L, et al
    Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
    Oral Oncol. 2024;159:107074.
    PubMed     Abstract available


  158. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
    Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
    Oral Oncol. 2024;159:107064.
    PubMed    


  159. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    PubMed     Abstract available


  160. TANG WZ, Xu WZ, Liu TH
    Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107065.
    PubMed    


  161. YACOUB I, Qian JY, Nashed K, Youssef M, et al
    Radiation techniques and advancements in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107060.
    PubMed    


  162. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
    Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
    Oral Oncol. 2024;157:106979.
    PubMed     Abstract available


  163. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    PubMed     Abstract available


  164. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
    Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107063.
    PubMed     Abstract available


    September 2024
  165. LECHIEN JR
    Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;159:107047.
    PubMed     Abstract available


  166. KEEFE K, McCrary HC, Wei M, Mark B, et al
    Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
    Oral Oncol. 2024;159:107041.
    PubMed     Abstract available


  167. DHARSHINI RAJATHIRAJAN S
    Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
    Oral Oncol. 2024;159:107053.
    PubMed    


  168. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    PubMed     Abstract available


  169. PRITHVIRAJ
    Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
    Oral Oncol. 2024;159:107054.
    PubMed    


  170. DINESHKUMAR R
    Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107052.
    PubMed    


  171. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
    The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
    Oral Oncol. 2024;159:107042.
    PubMed     Abstract available


  172. MIN Y, Liu X, Wei Z, Song G, et al
    Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2024;159:107028.
    PubMed     Abstract available


  173. RENGASAMY G, Priya Veeraraghavan V
    Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
    Oral Oncol. 2024;159:107035.
    PubMed    


  174. DHARSHINI RAJATHIRAJAN S
    Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
    Oral Oncol. 2024;159:107037.
    PubMed    


  175. DHARSHINI RAJATHIRAJAN S
    Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
    Oral Oncol. 2024;159:107036.
    PubMed    


  176. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
    Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107030.
    PubMed     Abstract available


  177. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
    Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
    Oral Oncol. 2024;159:107015.
    PubMed     Abstract available


  178. WANG A, Xia H, Li J, Diao P, et al
    Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107016.
    PubMed     Abstract available


  179. PRITHVIRAJ T
    Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107018.
    PubMed    


  180. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
    Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
    Oral Oncol. 2024;158:107012.
    PubMed     Abstract available


  181. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
    Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107011.
    PubMed     Abstract available


  182. ZHANG X, Zheng W, Huang S, Li H, et al
    Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
    Oral Oncol. 2024;158:107000.
    PubMed     Abstract available


  183. CHEN J, Cheng H, Liang Y, Lin J, et al
    The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
    Oral Oncol. 2024;156:106938.
    PubMed     Abstract available


    August 2024
  184. LECHIEN JR, Hans S
    Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;158:107009.
    PubMed     Abstract available


  185. ZHAO J, Ruan X, Wei S, Zheng X, et al
    The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
    Oral Oncol. 2024;158:107006.
    PubMed    


  186. YIN WJ, Mao W, Yang F, Wang MY, et al
    Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
    Oral Oncol. 2024;158:107001.
    PubMed     Abstract available


  187. GE Y, Liu H, Huang W, Zhu H, et al
    Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
    Oral Oncol. 2024;158:106999.
    PubMed     Abstract available


  188. T P
    Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
    Oral Oncol. 2024;158:107010.
    PubMed    


  189. ZHOU X, Shao T, Jia H, Hou L, et al
    Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:107008.
    PubMed     Abstract available


  190. PRASAD M
    DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
    Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
    PubMed    


  191. KNAP RABJERG H, Grau Eriksen J, Soby S
    Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107003.
    PubMed    


  192. DU F, Shao K, Yang Y, Bai X, et al
    Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
    Oral Oncol. 2024;158:106998.
    PubMed     Abstract available


  193. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
    The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
    Oral Oncol. 2024;158:107007.
    PubMed     Abstract available


  194. SUN L, Cohen RB, Dimitrios Colevas A
    Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Oral Oncol. 2024;158:106997.
    PubMed     Abstract available


  195. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    PubMed     Abstract available


  196. YUAN J, Wu M, Qiu L, Xu W, et al
    Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:106980.
    PubMed     Abstract available


  197. YANG R, Li R, Niu X, Zhao Y, et al
    Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
    Oral Oncol. 2024;158:106981.
    PubMed     Abstract available


  198. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
    Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;158:106986.
    PubMed     Abstract available


  199. PAN GS, Sun XM, Kong FF, Wang JZ, et al
    Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106987.
    PubMed     Abstract available


  200. QIN G, Liao X, Zhang B, Su Y, et al
    An individualized immune prognostic signature in nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106985.
    PubMed     Abstract available


  201. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    PubMed     Abstract available


  202. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
    Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
    Oral Oncol. 2024;157:106976.
    PubMed     Abstract available


  203. SANKAR S
    Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
    Oral Oncol. 2024;157:106977.
    PubMed    


  204. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
    The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;157:106978.
    PubMed     Abstract available


    July 2024
  205. MCDOWELL L, Gough K, White I, Corry J, et al
    Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
    Oral Oncol. 2024;157:106975.
    PubMed     Abstract available


  206. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
    Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
    Oral Oncol. 2024;157:106972.
    PubMed     Abstract available


  207. JEYARAJ G
    Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
    Oral Oncol. 2024;157:106974.
    PubMed    


  208. JEYARAJ G
    Letter to the editor, "Mutation detection in saliva from oral cancer patients".
    Oral Oncol. 2024;157:106929.
    PubMed    


  209. GANESH PS, Pathoor NN, Gopal RK
    Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;157:106954.
    PubMed     Abstract available


  210. LORINI L, Zigliani G, Morbini P, Salviato E, et al
    Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
    Oral Oncol. 2024;157:106950.
    PubMed     Abstract available


  211. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    PubMed     Abstract available


  212. SURESH S
    Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;157:106959.
    PubMed    


  213. WEN YF, Huang WJ, Chen XL, Cai HT, et al
    Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
    Oral Oncol. 2024;157:106963.
    PubMed     Abstract available


  214. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
    Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
    Oral Oncol. 2024;157:106942.
    PubMed     Abstract available


  215. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
    Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2024;157:106944.
    PubMed     Abstract available


  216. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
    Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
    Oral Oncol. 2024;157:106941.
    PubMed     Abstract available


  217. SHANMUGAM G
    Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
    Oral Oncol. 2024;157:106951.
    PubMed    


  218. MEIVELU MOOVENDHAN
    "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Oral Oncol. 2024;157:106940.
    PubMed    


  219. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
    In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
    Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
    PubMed    


  220. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
    Oral Oncol. 2024;156:106948.
    PubMed    


  221. SHANMUGAM G
    Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
    Oral Oncol. 2024;156:106952.
    PubMed    


  222. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
    A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;156:106946.
    PubMed     Abstract available


  223. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    PubMed     Abstract available


  224. SHANMUGAM G
    Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
    Oral Oncol. 2024;156:106935.
    PubMed    


  225. ARUMUGANAINAR D, Sekaran S
    Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
    Oral Oncol. 2024;156:106933.
    PubMed    


  226. GU LW, Zhang X, Zhang J, Xiao BB, et al
    The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2024;156:106928.
    PubMed     Abstract available


  227. SURESH S
    Commentary on 'Mutation detection in saliva from oral cancer patients'.
    Oral Oncol. 2024;156:106937.
    PubMed    


  228. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
    Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
    Oral Oncol. 2024;156:106934.
    PubMed    


  229. KANNAN R
    Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2024;156:106936.
    PubMed    


  230. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    PubMed    


  231. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
    Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
    Oral Oncol. 2024;154:106808.
    PubMed     Abstract available


  232. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    PubMed     Abstract available


  233. SATHISHKUMAR K
    Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
    Oral Oncol. 2024;156:106931.
    PubMed    


  234. HARIDEVAMUTHU B
    Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Oral Oncol. 2024;156:106913.
    PubMed    


    June 2024
  235. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
    Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
    Oral Oncol. 2024;156:106917.
    PubMed     Abstract available


  236. ZHAO X, Zhou Y, Peng G, Wen L, et al
    Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2024;156:106918.
    PubMed     Abstract available


  237. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;156:106911.
    PubMed    


  238. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;156:106912.
    PubMed    


  239. JEYARAJ G
    Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
    Oral Oncol. 2024;156:106906.
    PubMed    


  240. DONG S, Bei W, Lin L, Jiang Y, et al
    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
    Oral Oncol. 2024;156:106908.
    PubMed     Abstract available


  241. JEYARAJ G
    Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
    Oral Oncol. 2024;156:106896.
    PubMed    


  242. SHANMUGAM G
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
    Oral Oncol. 2024;156:106915.
    PubMed    


  243. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    PubMed     Abstract available


  244. HARIDEVAMUTHU B
    Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
    Oral Oncol. 2024;155:106902.
    PubMed    


  245. MEIVELU MOOVENDHAN
    Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2024;155:106903.
    PubMed    


  246. PRASAD M, Sekar R, Murugan R
    Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;155:106899.
    PubMed    


  247. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
    Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
    Oral Oncol. 2024;155:106904.
    PubMed    


  248. TOPKAN E, Somay E, Bascil S, Selek U, et al
    Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;155:106898.
    PubMed    


  249. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    PubMed    


  250. LEI S, Chen L, Ji P, Li K, et al
    Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
    Oral Oncol. 2024;155:106891.
    PubMed     Abstract available


  251. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
    Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
    Oral Oncol. 2024;155:106877.
    PubMed    


  252. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    PubMed     Abstract available


  253. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
    Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
    PubMed    


  254. PRASAD M, Murugan R
    Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
    Oral Oncol. 2024;155:106890.
    PubMed    


  255. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
    Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
    Oral Oncol. 2024;155:106879.
    PubMed    


  256. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
    Oral Oncol. 2024;155:106878.
    PubMed    


  257. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    PubMed    


  258. PACE GM, Costantino A, Festa BM, Spriano G, et al
    Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
    Oral Oncol. 2024;153:106299.
    PubMed    


  259. LU HA, Wang YM, Chih Chen W, Wu CN, et al
    Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
    Oral Oncol. 2024;154:106864.
    PubMed     Abstract available


  260. KRC R, Mendes W, Molitoris J, Ferris M, et al
    Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
    Oral Oncol. 2024;154:106875.
    PubMed     Abstract available


    May 2024
  261. XU W, Qiu L, Li F, Fei Y, et al
    Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;154:106865.
    PubMed     Abstract available


  262. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
    Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2024;154:106868.
    PubMed     Abstract available


  263. PARK R, Li J, Slebos RJC, Chaudhary R, et al
    Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;154:106866.
    PubMed     Abstract available


  264. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;154:106858.
    PubMed    


  265. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
    The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
    Oral Oncol. 2024;154:106863.
    PubMed    


  266. ABBACI M, Villard A, Auperin A, Asmandar S, et al
    Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
    Oral Oncol. 2024;154:106862.
    PubMed     Abstract available


  267. YAO Y, Ouyang Q, Wang S, Li K, et al
    Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Oral Oncol. 2024;154:106867.
    PubMed     Abstract available


  268. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
    Oral Oncol. 2024;154:106856.
    PubMed    


  269. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    PubMed     Abstract available


  270. PEZZULLA D, Re A, Ferro M, Cilla S, et al
    Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
    Oral Oncol. 2024;154:106837.
    PubMed    


  271. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
    Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
    Oral Oncol. 2024;154:106840.
    PubMed    


  272. HE S, Yu H, He L, Liu M, et al
    Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
    Oral Oncol. 2024;154:106827.
    PubMed     Abstract available


  273. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
    An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
    Oral Oncol. 2024;154:106826.
    PubMed     Abstract available


  274. DE FELICE F, Guerrero Urbano T
    Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
    Oral Oncol. 2024;154:106836.
    PubMed    


  275. HAN N, Zhou D, Ruan M, Yan M, et al
    Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
    Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
    PubMed    


  276. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
    Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;153:106833.
    PubMed     Abstract available


  277. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
    The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;153:106799.
    PubMed     Abstract available


  278. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
    Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
    Oral Oncol. 2024;153:106834.
    PubMed     Abstract available


  279. XU Y, Xu T, Yao Q, Chen J, et al
    Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
    Oral Oncol. 2024;153:106828.
    PubMed     Abstract available


  280. ALMANGUSH A, Makitie AA, Leivo I
    Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
    Oral Oncol. 2024;153:106829.
    PubMed    


  281. DAS R, Misra SR
    Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;153:106832.
    PubMed    


  282. DHARMALINGAM JOTHINATHAN MK
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106811.
    PubMed    


  283. POOJARI M, Madabhavi I, Desai S
    Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
    Oral Oncol. 2024;152:106789.
    PubMed     Abstract available


  284. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106783.
    PubMed     Abstract available


    April 2024
  285. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
    Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
    Oral Oncol. 2024;153:106813.
    PubMed     Abstract available


  286. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
    Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
    Oral Oncol. 2024;153:106729.
    PubMed     Abstract available


  287. FANG Q, Yuan J, Zhang X, Dai L, et al
    Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
    Oral Oncol. 2024;152:106810.
    PubMed     Abstract available


  288. YEO BSY, Lee RS, Lim NE, Tan E, et al
    Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Oral Oncol. 2024;152:106786.
    PubMed     Abstract available


  289. LI Y, Zhou Y, Zhao C, Liu L, et al
    The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
    Oral Oncol. 2024;152:106798.
    PubMed     Abstract available


  290. RAMASAMY P, Sekaran S, Ganapathy D
    Oral cancer burden in tribal populations residing in India.
    Oral Oncol. 2024;152:106801.
    PubMed    


  291. SEKAR D
    Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106800.
    PubMed    


  292. SARAVANAN M
    Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
    Oral Oncol. 2024;152:106806.
    PubMed    


  293. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
    Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;152:106802.
    PubMed    


  294. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
    Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
    Oral Oncol. 2024;152:106803.
    PubMed    


  295. KONO M, Saito S, Rokugo M, Egloff AM, et al
    Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Oral Oncol. 2024;152:106795.
    PubMed     Abstract available


  296. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
    Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
    Oral Oncol. 2024;152:106784.
    PubMed     Abstract available


  297. SIVAPERUMAL P, Ganapathy D, Kamala K
    Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
    Oral Oncol. 2024;152:106794.
    PubMed    


  298. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
    Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
    Oral Oncol. 2024;152:106793.
    PubMed     Abstract available


  299. SARAVANAN M
    Comment on "The microbiome and oral cancer: More questions than answers".
    Oral Oncol. 2024;152:106792.
    PubMed    


  300. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
    Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Oral Oncol. 2024;152:106788.
    PubMed    


  301. DAS R, Misra SR, Nayak A
    Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
    Oral Oncol. 2024;152:106790.
    PubMed    


  302. XIAO X, Shi Z, Song Z
    Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
    Oral Oncol. 2024;152:106785.
    PubMed    


  303. GASNE C, Atallah S, Dauzier E, Thariat J, et al
    Twelve years after: The french national network on rare head and neck tumours (REFCOR).
    Oral Oncol. 2024;151:106762.
    PubMed     Abstract available


  304. MALI SB
    Role of telemedicine in head neck cancer.
    Oral Oncol. 2024;151:106746.
    PubMed     Abstract available


  305. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
    Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
    Oral Oncol. 2024;151:106742.
    PubMed     Abstract available


    March 2024
  306. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
    Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Oral Oncol. 2024;152:106778.
    PubMed     Abstract available


  307. LORINI L, Gili R, Salvestrini V, Morelli I, et al
    De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Oral Oncol. 2024;152:106768.
    PubMed     Abstract available


  308. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
    An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;152:106750.
    PubMed     Abstract available


  309. HONG RL, Yen CJ, Lien MY, Cheng R, et al
    Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106760.
    PubMed     Abstract available


  310. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
    Oral Oncol. 2024;152:106744.
    PubMed     Abstract available


  311. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
    Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Oral Oncol. 2024;151:106752.
    PubMed     Abstract available


  312. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    PubMed     Abstract available


  313. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    PubMed    


  314. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    PubMed    


  315. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    PubMed    


  316. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    PubMed     Abstract available


  317. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    PubMed     Abstract available


  318. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    PubMed     Abstract available


  319. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    PubMed    


  320. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    PubMed     Abstract available


  321. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    PubMed     Abstract available


  322. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    PubMed     Abstract available


  323. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available


    February 2024
  324. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    PubMed     Abstract available


  325. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    PubMed     Abstract available


  326. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.